Search

In a retrospective study, three elderly patients developed hypervitaminosis-D or vitamin-D intoxication leading to hypercalcaemia or cardiac arrest during treatment for vitamin-D deficiency. One patient developed severe hypercalcaemia, while the other two patients experienced cardiac arrest. One patient also developed necrotising pancreatitis. Unfortunately, all three patients died. [Extracted from the article]

In a case report from a phase ia study, a patient with refractory advanced solid tumors experienced serious adverse reactions while receiving treatment with topotecan and elimusertib. The patient developed respiratory failure, cardiac arrest, and pancytopenia. The specific details regarding the duration of treatment, patient outcomes, and routes of administration were not provided. These findings highlight the potential risks associated with this combination therapy for advanced solid tumors. [Extracted from the article]

A study conducted between April 2013 and November 2015 described four patients with acute myeloid leukemia who experienced various toxicities while being treated with idarubicin and cytarabine. The patients developed hypotension complicated by stroke and cardiac arrest, acute kidney injury, congestive heart failure, and congestive heart failure with concurrent arrhythmia. The treatment was discontinued for all patients. The study did not provide information about the patients' ages, sexes, duration of treatment to reaction onset, or outcomes. [Extracted from the article]

A case report in the journal Reactions Weekly describes the toxicities experienced by a 41-year-old woman who intentionally overdosed on benzonatate. The woman suffered a seizure, cardiac arrest, mixed acidosis, sinus tachycardia, and QRS widening. Emergency services were called, and after two rounds of advanced cardiovascular life support, circulation was restored. The woman received treatment for her symptoms and was eventually discharged for ongoing management. The adverse reactions were attributed to the intentional overdose of benzonatate. [Extracted from the article]

A retrospective analysis study involving seven patients was conducted to examine the efficacy of atropine, charcoal, and sodium bicarbonate in treating tolfenpyrad poisoning and metabolic acidosis. Three case reports were described, involving patients of various ages and genders. In all three cases, the interventions of atropine, charcoal, and sodium bicarbonate did not result in clinical efficacy, and the patients ultimately died due to the poisoning. The lack of efficacy was attributed to sodium bicarbonate in all three cases, while atropine and charcoal were also implicated in one case. [Extracted from the article]

An elderly woman experienced cardiac arrest while being treated with iopamidol for a CT angiography. She had a history of a cavernous internal carotid artery aneurysm and multiple drug allergies, including to iodinated contrast mediums. The woman also had mild renal impairment and a carotid cavernous fistula. After a multidisciplinary discussion, she underwent an endovascular intervention using gadolinium-based contrast agents, which resulted in improved neurological deficits. [Extracted from the article]

Two case reports are presented in this article, highlighting potential adverse effects of testosterone and testosterone-enanthate treatment for erectile dysfunction. In the first case, a 43-year-old man experienced acute chest pain and cardiac arrest after four months of testosterone-enanthate treatment, ultimately resulting in his death. Autopsy findings revealed coronary artery obstructions. In the second case, a 48-year-old man developed acute dyspnea and tachycardia after six months of testosterone treatment, and was subsequently diagnosed with a pulmonary artery thrombus and factor V Leiden mutation. These cases suggest a potential link between testosterone therapy and acute cardiac events and factor V Leiden mutation. [Extracted from the article]

In a study of 21 adult patients with mantle cell lymphoma, one patient experienced cardiac arrest and sepsis while being treated with bendamustine and off-label obinutuzumab. The patient received BO induction therapy, which included IV bendamustine and IV obinutuzumab. However, the patient developed grade 5 cardiac arrest with sepsis as a result of the treatment. The specific details of the patient's age, sex, and treatment duration were not provided. [Extracted from the article]

A case report published in Reactions Weekly describes the lack of efficacy of multiple drugs in the treatment of a 31-year-old pregnant woman with COVID-19 pneumonia. The woman initially presented with joint pain and was found to have vaso occlusive crisis and COVID-19 infection. She received various treatments including opioid analgesics, but her condition worsened and she was diagnosed with acute chest syndrome. Despite receiving remdesivir, dexamethasone, heparin, and paracetamol, her oxygen requirements increased rapidly and she ultimately experienced cardiopulmonary arrest. This case highlights the challenges of treating COVID-19 pneumonia in pregnant patients and the need for further research in this area. [Extracted from the article]

In a study involving 80 patients with advanced or recurrent endometrial cancer, two women experienced serious adverse events related to their treatment. The first woman developed cardiac arrest and died after receiving dostarlimab and salbutamol. The second woman, despite receiving dostarlimab, also died from endometrial cancer. These cases suggest a lack of efficacy in the treatment of endometrial cancer with dostarlimab. [Extracted from the article]

A 70-year-old woman with cardiac sarcoidosis experienced lack of efficacy during treatment with dobutamine, milrinone, and norepinephrine for cardiogenic shock. She had uveitis and bilateral hilar lymphadenopathy, and was admitted for syncope and received a temporary pacemaker. Despite receiving IV dobutamine, milrinone, and norepinephrine, her blood pressure remained low. Additional treatments were introduced, and her condition improved over time. At a 3-month follow-up, she had no recurrence of ventricular arrhythmia and normal left ventricular contraction. [Extracted from the article]

A 35-year-old man experienced cardiac arrest after receiving sulfur-hexafluoride for ECG enhancement. He also showed lack of efficacy when treated with various medications for venous thromboembolism prophylaxis and cardiac arrest. The man had a history of multiple sclerosis, obesity, and other medical conditions. Despite receiving multiple interventions, including epinephrine and extracorporeal membrane oxygenation, he ultimately died from the cardiac arrest. [Extracted from the article]

A retrospective study of 46 children with early-stage non-Hodgkin's lymphoma (ES-NHL) found that one child developed cardiac arrest during treatment with doxorubicin, resulting in death. Another child exhibited lack of efficacy during treatment with cyclophosphamide, vincristine, and methotrexate. Despite receiving treatment, disease progression was observed in the second child, indicating lack of efficacy to the drugs. The child was ultimately successfully treated with the institutional protocol for advanced-stage disease. [Extracted from the article]

An 88-year-old man experienced QT prolongation and torsade de pointes, leading to cardiac arrest while taking mirtazapine. The man had pre-existing conditions including arterial hypertension, cognitive impairment, sinus node disease, and congenital long QT syndrome. He was treated with cardiopulmonary resuscitation and shock therapy, and his treatment with mirtazapine was stopped. The man's QT segment gradually reduced with the use of nadolol, and no further arrhythmic events occurred. The article suggests that the cardiac arrest was likely caused by mirtazapine. [Extracted from the article]

A 53-year-old man experienced drug intolerance while being treated for acute B-cell lymphoblastic leukemia (B-ALL) with cyclophosphamide and dexamethasone. He had a history of high body temperature, weakness, and loss of appetite. The treatment caused severe infection and myelosuppression, leading to his admission to the emergency department for malignant hypercalcemia. The man was diagnosed with B-ALL progression, hypercalcemia, and osteolytic bone lesions, which were attributed to his poor tolerance of the chemotherapy. Despite treatment with high-dose dexamethasone and bisphosphonates, his condition worsened, and he died from sudden cardiac arrest three days after receiving chemotherapy. [Extracted from the article]

A 49-year-old man experienced cardiac arrest while being treated for atrial fibrillation (Afib) with propranolol. He also showed lack of efficacy when treated with diltiazem and thiamazole for Afib with rapid ventricular rate or thyrotoxicosis. The man was admitted to the hospital with palpitations and received treatment with diltiazem, which did not improve his heart rate. Further investigation revealed thyrotoxicosis, and he started receiving treatment with thiamazole and propranolol. Shortly after, he experienced hypotension and bradycardia, leading to cardiac arrest. He was diagnosed with cardiac arrest secondary to propranolol and thyroid storm due to lack of efficacy of thiamazole. After receiving treatment, his condition improved, and he was discharged on losartan and aspirin for cardiomyopathy and thiamazole for thyrotoxicosis. [Extracted from the article]

In a single-center observational study, four adult patients with severe COVID-19 were described who exhibited lack of efficacy or developed drug-induced liver injury while receiving off-label treatment with dexamethasone or tocilizumab. Despite receiving dexamethasone, their condition did not improve, indicating lack of efficacy. Some patients also received tocilizumab, but one patient died due to sudden cardiac arrest associated with pulmonary embolism, indicating lack of efficacy to tocilizumab. Another patient developed mild, asymptomatic, and self-limiting drug-induced liver injury secondary to tocilizumab. [Extracted from the article]

A 79-year-old woman with a history of coronary artery disease and cardiac arrest was admitted to the hospital for weakness, nausea, and vomiting. She had recently removed multiple ticks from her body and was diagnosed with Lyme disease and babesia coinfection. She was treated with doxycycline, azithromycin, and atovaquone, but experienced sudden dyspnea and chest tightness. She was transferred to the ICU, intubated, and diagnosed with stress-induced/Takotsubo cardiomyopathy with severe pulmonary hypertension. Despite resuscitation efforts, she ultimately died from fulminant myocarditis, indicating a lack of efficacy of the treatment. [Extracted from the article]

American Health Packaging, on behalf of BluePoint Laboratories, is voluntarily recalling 21 batches of Potassium Chloride Extended-Release Capsules due to failed dissolution. This may lead to patients developing hyperkalaemia, severe muscle weakness, arrhythmias, and cardiac arrest. However, as of June 25, 2024, there have been no reports of hyperkalaemia or serious adverse events. The recalled lots have expiry dates ranging from July 31, 2024, to September 30, 2025. Wholesalers, distributors, and retailers with the recalled products should stop distributing them immediately, and consumers with the affected lots should consult their healthcare provider before discontinuing use. [Extracted from the article]

A 45-year-old woman with acquired hemophilia (AH) experienced a lack of efficacy with factor VIII treatment. She presented to the emergency department with symptoms of spontaneous hemoptysis and odynophagia, and was diagnosed with AH. Despite receiving factor VIII, she did not respond to the treatment. She subsequently developed brain edema, respiratory distress, and other complications, including sepsis and COVID-19. Despite attempts at resuscitation, she ultimately died due to the progression of AH. The failure of factor VIII treatment was considered a contributing factor to her death. [Extracted from the article]

This article from Reactions Weekly reports on a case involving a 5-day-old male neonate who experienced cardiac arrest during treatment with adenosine. The neonate had multiple pre-existing conditions, including muscular ventricular septal defect, hypoplastic left heart syndrome, and severe tricuspid regurgitation. After undergoing a successful ventricular assist device placement, the neonate experienced complications and required various interventions. Unfortunately, the neonate's condition worsened, leading to multiorgan failure and death. [Extracted from the article]

An 18-year-old woman experienced drug toxicity after intentionally overdosing on propafenone, a medication used to treat irregular heart rhythms. She exhibited symptoms such as seizures, bradycardia (slow heart rate), hypotension (low blood pressure), metabolic acidosis, cardiac arrest, and coma. The woman received medical treatment including gastric lavage, charcoal administration, cardiopulmonary resuscitation, mechanical ventilation, and various medications. She eventually recovered fully and was discharged from the hospital. [Extracted from the article]

An 18-year-old woman experienced drug toxicity after intentionally overdosing on propafenone, a medication used to treat irregular heart rhythms. She ingested a large amount of propafenone and was admitted to the hospital one hour later. She experienced seizures, bradycardia (slow heart rate), hypotension (low blood pressure), metabolic acidosis (excess acid in the body), cardiac arrest, and coma. The woman received treatment including gastric lavage, charcoal administration, cardiopulmonary resuscitation, mechanical ventilation, and other supportive measures. She eventually recovered fully and was discharged from the hospital. [Extracted from the article]

A woman in her 80s experienced a lack of efficacy while being treated with epinephrine for cardiopulmonary arrest. She presented at a hospital with chest and upper abdominal discomfort and vomiting, and was diagnosed with cardiopulmonary arrest based on physical examination and electrocardiography findings. Despite receiving epinephrine, cardiac massage, and fluid resuscitation therapy, she ultimately died. Autopsy findings indicated that the cause of death was cardiopulmonary arrest and Clostridium perfringens septicaemia, suggesting that the epinephrine treatment was not effective. [Extracted from the article]

A 26-year-old man with pulmonary hypertension experienced a lack of efficacy while being treated with multiple drugs, including furosemide, lisinopril, eplerenone, warfarin, tadalafil, and bisoprolol. The man had a history of heart problems, including a ventricular septal defect and rheumatic mitral regurgitation. Despite being on various medications, his symptoms worsened, and he ultimately died of sudden cardiac death. This case highlights the need for further research and understanding of the effectiveness of these drugs in treating pulmonary hypertension. [Extracted from the article]

A 40-year-old woman experienced cardiac arrest while being treated with clozapine for schizoaffective disorder. The woman had not received the medication for nearly 2 weeks due to issues with her psychiatrist's certification. After restarting her treatment, she experienced cardiac arrest one hour after receiving her first dose of clozapine. Despite attempts at resuscitation, she suffered cerebral hypoxia and shock. [Extracted from the article]

A 79-year-old man experienced complete heart block and cardiac arrest during two separate instances of general anesthesia. The first incident occurred during treatment with sugammadex, and the second occurred during treatment with propofol. The man had a history of coronary artery disease, hypertension, paroxysmal atrial fibrillation, and a left bundle branch block. He received medical care and ultimately underwent the insertion of a permanent dual chamber pacemaker. [Extracted from the article]

A 78-year-old man experienced cardiac arrest while being treated with labetalol for a hypertensive crisis. The man had pre-existing conditions of coronary artery disease and adrenal pheochromocytoma. After receiving IV labetalol, he went into cardiac arrest and required cardiopulmonary resuscitation. He was eventually stabilized and discharged with a different medication regimen. [Extracted from the article]

In a study of 200 pediatric patients, it was found that some patients experienced bradycardia, cardiac arrest, or complications during surgery due to the use of ketamine anesthesia. The specific details of the patients' ages, genders, and treatment regimens were not provided. One patient developed bradycardia, another experienced cardiac arrest in the recovery room, and a third patient required a small operation at the rectum due to complications. Unfortunately, the patient who underwent the rectal operation died after being intubated. [Extracted from the article]

This document provides a list of recently published scientific literature on drug safety-related adverse reactions. The articles cover a range of topics, including sudden cardiac death or ventricular arrhythmia in patients taking certain medications, ocular adverse events following CAR-T cell therapy, neurodevelopmental and functional outcomes in babies exposed to antiseizure medication in utero, patient-reported adverse events and treatment discontinuation in multiple myeloma patients, the relationship between a specific medication and non-hematological malignant tumors, immune-related adverse events associated with immune checkpoint inhibitors for metastatic renal cell carcinoma, and adverse events with a particular medication in the real world. These articles offer valuable insights for researchers and individuals interested in understanding the potential risks and side effects of various medications. [Extracted from the article]

A 25-year-old pregnant woman experienced lack of efficacy while being treated with spironolactone for left-ventricular dysfunction. She had a history of abnormal electrocardiography findings and complained of palpitations and dyspnea during exercise. After switching to spironolactone, she developed decompensated heart failure and frequent nonsustained ventricular tachycardia. The woman underwent an emergency caesarean section and gave birth to a healthy baby. She later received an implantable cardioverter-defibrillator and was being considered for a heart transplant. [Extracted from the article]

A 66-year-old man experienced cardiac arrest after receiving suxamethonium chloride for muscle relaxation. The patient had a history of medical conditions including septic shock, pneumonia, cerebral vascular accident, respiratory failure, and seizure disorder. The administration of suxamethonium chloride resulted in widening of the QRS complex on telemetry, leading to pulseless electrical activity arrest. Cardiopulmonary resuscitation was performed, and the patient was successfully revived. The cardiac arrest was attributed to the use of suxamethonium chloride. [Extracted from the article]

In a retrospective study of 52 patients with chronic phase chronic myeloid leukemia (CML), two patients developed cardiac arrest and myocardial infarction while being treated with nilotinib. One patient had pre-existing conditions of coronary artery disease, hypertension, and diabetes and experienced fatal cardiac arrest 80 months after dose de-escalation. The other patient developed myocardial infarction while receiving a de-escalated dose and was subsequently switched to asciminib. The study does not provide information on the ages or sexes of the patients. [Extracted from the article]

A 35-year-old woman with a medical history of hepatitis C, moderate persistent asthma, and HIV exhibited no response to magnesium-sulfate and prednisone for an asthma exacerbation. During treatment with methylprednisolone, she experienced anaphylaxis, resulting in cardiac arrest. She was transferred to the ICU for status asthmaticus and received treatment with albuterol, dexamethasone, and helium/oxygen, which resolved her bronchospasm. However, she developed anoxic encephalopathy as a complication of the cardiac arrest and required a tracheostomy. [Extracted from the article]

A 62-year-old woman experienced QTc prolongation, secondary torsades de pointes, and cardiac arrest as a result of a drug-drug interaction between remdesivir and azithromycin. The woman had been admitted to the hospital with shortness of breath and was diagnosed with COVID-19 and bacterial pneumonia. Despite correcting electrolyte abnormalities and discontinuing the medications, the torsades de pointes continued to recur. The woman eventually received isoproterenol and a transvenous pacer, and her condition improved over the course of 10 days. She was discharged on nadolol. [Extracted from the article]

The European Medicines Agency (EMA) has released recommendations regarding liposomal amphotericin B-related hyperkalaemia, a condition where high levels of potassium are found in the blood. The EMA has required Marketing Authorisation Holders (MAHs) of liposomal amphotericin B formulations, such as AmBisome and Abelcet, to update their product information. The updates include warnings about the risk of hyperkalaemia, particularly in patients with renal impairment or those taking nephrotoxic medications. These updates aim to ensure that healthcare professionals are aware of the potential adverse effects of these medications. [Extracted from the article]

A retrospective study conducted in Taiwan found that the use of haloperidol or quetiapine increases the risk of severe QT-interval prolongation (SQTP). The study analyzed data from electronic medical records of patients who received quetiapine or haloperidol between 2001 and 2019. It was found that 13.0% of quetiapine recipients and 14.2% of haloperidol recipients developed SQTP. Risk factors for SQTP included age over 65 years, heart failure, hypokalemia, concomitant use of amiodarone, and baseline QTc interval. The study also revealed that SQTP in quetiapine-treated patients was associated with an increased risk of ventricular arrhythmias and sudden cardiac death. [Extracted from the article]

A study examined the cardiotoxicity of trastuzumab, a drug used to treat HER2 positive breast cancer. The study included 117 patients and found that three women experienced cardiac issues during treatment. One woman developed asymptomatic cardiotoxicity, another developed symptomatic cardiotoxicity, and a third woman experienced sudden cardiac death. The study did not provide information on the final outcomes of these adverse reactions or the duration of treatment before the onset of these reactions. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 45-year-old-man developed torsades-de-pointes (TdP) during treatment with haloperidol for delirium. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 65-year-old man developed ventricular fibrillation and cardiac arrest during treatment with nivolumab and ipilimumab for non-small cell lung cancer [dosages, routes and times to reactions onsets not stated]. [Extracted from the article]

A retrospective study examined 19 patients aged 55-92 years who developed haemorrhagic conversion of acute ischemic stroke while being treated with alteplase. Additionally, six of these patients showed lack of efficacy when treated with aminocaproic acid for haemorrhagic conversion of acute ischemic stroke. All patients received alteplase, with doses ranging from 6-9mg bolus and 49-81mg infusion, and experienced haemorrhagic conversion of acute ischemic stroke as a result. Some patients also received cryoprecipitate and aminocaproic acid, but six of them experienced thromboembolic complications despite the treatment. Unfortunately, seven patients died due to cardiac arrest, haemorrhagic conversion, or withdrawal of care. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is: Drug overdose• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA man in his 60s [exact age at the time of reaction onset not stated] developed ventricular fibrillation cardiac arrest following an intentional overdose of nicorandil and ranolazine for cardiac disorder with suicidal ideation [route and dosage not stated]. [Extracted from the article]

A case report published in Reactions Weekly describes the toxicities experienced by a man in his 50s who abused and overdosed on bupropion. The man had a history of head trauma, behavioral disorder, and substance abuse. He was admitted to the emergency room after intentionally overdosing on bupropion, experiencing psychomotor agitation and dyspnea. He was later diagnosed with a type 2 acute myocardial infarction. The man admitted to long-term abuse of bupropion and continued to abuse the drug even after discharge. Despite recommendations for psychiatric hospitalization, he refused and ultimately died at home from cardiopulmonary arrest. [Extracted from the article]

A case report published in Reactions Weekly describes a 30-year-old woman with COVID-19 pneumonia who experienced episodes of asystole, a type of cardiac arrest. The woman was treated with atropine and dopamine, but these medications were ineffective in stopping the asystole episodes. She was then treated with theophylline, which resolved the episodes, but her condition continued to deteriorate and she ultimately died. This case highlights the lack of efficacy of atropine and dopamine in treating asystole in this particular patient. [Extracted from the article]

A 20-year-old woman experienced silicon embolisation syndrome after receiving silicon for an undisclosed reason. She presented to the emergency room with shortness of breath and chest pain, and her condition worsened over time. Despite medical intervention, including intubation and mechanical ventilation, she ultimately experienced prolonged cardiac arrest and died. Autopsy findings confirmed the presence of silicone deposits in her lungs, leading to the diagnosis of silicon embolisation syndrome. [Extracted from the article]

This article from Reactions Weekly describes two case reports of patients who experienced lack of effectiveness with multiple drugs. The first case involves a 4-month-old girl who died after receiving treatment for hypotension, hyperkalemia, and cardiac arrest. The second case involves a 12-year-old boy who experienced cardiac arrest following a self-inflicted asphyxiation episode and did not respond to treatment. Both cases highlight the challenges of treating these conditions and the need for further research. [Extracted from the article]

This article presents two case reports of men who experienced cytomegalovirus (CMV) reactivation while undergoing treatment for renal transplant rejection. In both cases, the patients were receiving immunosuppressant drugs such as tacrolimus, mycophenolate mofetil, and prednisone. Despite treatment with ganciclovir and other medications, the patients exhibited a lack of efficacy in controlling CMV reactivation. Unfortunately, one patient ultimately died due to cardiac arrest and CMV infection. These case reports highlight the challenges of managing CMV reactivation in transplant patients and the need for further research in this area. [Extracted from the article]

In a retrospective study of 88 patients admitted to the hospital for upper gastrointestinal bleeding, three patients experienced stroke or cardiac arrest after receiving sedation with either propofol or midazolam during an upper gastrointestinal endoscopy. The specific dosages, durations of treatment, and outcomes were not provided. One patient developed stroke as a result of propofol therapy, while another patient experienced stroke and the third patient had cardiac arrest as a result of midazolam therapy. [Extracted from the article]

A case report published in Reactions Weekly describes the aggravation of a subarachnoid hemorrhage in a 63-year-old patient during anticoagulant therapy with heparin. The patient experienced cardiac arrest and received CPR, followed by advanced life support and the administration of medications. Despite efforts to stabilize the patient, they deteriorated into recurrent ventricular fibrillation. Extracorporeal membrane oxygenation was initiated, and the patient underwent further interventions, including defibrillation and stenting of a blocked coronary artery. Unfortunately, the patient ultimately died due to the traumatic subarachnoid hemorrhage and potential exacerbation caused by heparin treatment. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is: Drug overdose• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA man in his early 20s [exact age not stated] developed anticholinergic toxidrome, Brugada pattern and cardiac arrest following drug poisoning with diphenhydramine at an intentional overdose for suicide attempt. Additionally, he exhibited lack of efficacy during treatment with epinephrine for cardiac arrest [not all routes stated]. [Extracted from the article]